Apheresis Market Size by Product, Procedure, Technology, Application, End-User & Region for 2024-2031

Apheresis Market Size And Forecast 2024-2031

The Apheresis Market is witnessing significant growth due to rising incidences of blood-related disorders and the increasing demand for therapeutic apheresis procedures. Technological advancements in apheresis devices and disposables are also contributing to the market's expansion, enhancing treatment efficacy. This is likely to enable the market size to surpass USD 3.99 Billion valued in 2024 to reach a valuation of around USD 6.3 Billion by 2031.

The market is expanding globally, with North America as the leading region. Key drivers include increasing healthcare investments and rising awareness of therapeutic apheresis. Emerging markets in Asia-Pacific are also gaining traction, driven by growing patient populations and improving healthcare infrastructure. The rising demand for apheresis is enabling the market to grow at aCAGR of 12.6% from 2024 to 2031.

Definition/Overview

Apheresis is a medical procedure used to separate and remove specific blood components, such as plasma, platelets, or white blood cells, while returning the remaining blood to the patient.

Apheresis is widely used in treating autoimmune disorders, hematological diseases and cardiovascular conditions. It also supports blood donations, including plasma and platelet collection, improving patient care in various clinical settings.

The apheresis market is poised for future growth, driven by advancements in technology, expanding healthcare infrastructure and increasing demand for blood component therapies, particularly in emerging markets.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

How Does the Rising Prevalence of Blood-Related Disorders Help in Driving the Growth Of The Apheresis Market?

The increasing frequency of blood-related ailments, such as autoimmune diseases, hematologic malignancies, and cardiovascular problems, is driving the apheresis industry. As these conditions frequently necessitate particular blood component therapy, the demand for apheresis procedures, which separate and collect targeted blood components, grows. Furthermore, innovations in apheresis technology and increasing awareness among healthcare professionals about the benefits of these procedures help to drive market expansion. Increasing investment in apheresis research and development expands treatment options and improves patient outcomes. Furthermore, the growing geriatric population, which is more sensitive to blood problems, increases the demand for effective apheresis treatments, driving market growth. Overall, the increasing prevalence of blood-related illnesses is a significant driver of the apheresis market.

How Is the High Cost of Apheresis Procedures Challenging the Growth Of The Apheresis Market?

The high cost of apheresis operations significantly limits the market's expansion. These treatments frequently necessitate specialized equipment, expert personnel, and substantial hospital resources, resulting in increasing operating expenses. As a result, many healthcare providers may hesitant to invest in apheresis technology, reducing patient access to these treatments. Furthermore, the high costs can put a strain on individuals and healthcare systems, particularly in areas with limited insurance coverage or financial resources. This expensive barrier may prevent patients from choosing for apheresis, reducing market demand. Furthermore, competition from less expensive alternative treatments may impede the apheresis market's growth. Overall, the high prices of apheresis operations represent a significant barrier to long-term industry growth.

Category-wise Acumens

How Will the Increasing Adoption of Automated Technologies Drive the Growth of The Apheresis Devices Segment?

The increasing adoption of automated technologies in apheresis devices is driving the growth of the segment by enhancing procedure accuracy, reducing manual errors and improving patient outcomes. These advanced devices offer greater efficiency in blood component separation, leading to their widespread use in both therapeutic and donation settings. As healthcare providers prioritize automation for better results and time savings, the demand for apheresis devices continues to grow, boosting the market segment's expansion.

How Will the Rising Use of Apheresis in Treating Autoimmune Disorders Drive the Growth of The Application Segment?

The rising use of apheresis in treating autoimmune disorders is driving growth in the Application segment by providing effective, targeted therapies for conditions like multiple sclerosis and Guillain-Barre syndrome. Apheresis helps remove harmful antibodies or immune complexes, offering significant clinical benefits. As the prevalence of autoimmune diseases increases, the demand for apheresis treatments expands, leading to the growth of this segment in both therapeutic and healthcare applications.

Country/Region-wise Acumens

Will The Advanced Healthcare Infrastructure Drive the Dominance of North America in The Apheresis Market?

North America's advanced healthcare infrastructure contributes significantly to the region's supremacy in the apheresis market. The well-established healthcare infrastructure make it easier to integrate innovative technologies, resulting in more efficient apheresis processes. Significant investments in cutting-edge medical technology improve the efficacy and accessibility of these therapies. Furthermore, growing awareness of the therapeutic benefits of apheresis, particularly for autoimmune diseases and hematologic disorders, is broadening the patient base. The region also benefits from a strong research climate, which promotes advances in apheresis technology. Additionally, regulatory backing and increasing healthcare expenditure help to drive market expansion. These factors combine to establish North America as a market leader in apheresis, fueling its sustained growth.

Will The Growing Healthcare Investments and Expanding Patient Population Drive the Rapid Growth of Asia-Pacific in The Apheresis Market?

The growing healthcare investments and expanding patient population are key drivers of Asia-Pacific's rapid growth in the Apheresis Market. As countries like China and India enhance their healthcare infrastructure, demand for advanced therapeutic procedures increases. Additionally, the rising prevalence of blood-related disorders and increasing awareness of apheresis treatments fuel market expansion. This combination of factors is positioning Asia-Pacific as the fastest-growing region in the global apheresis market.

Competitive Landscape

The apheresis market is a dynamic and competitive space, characterized by a diverse range of players vying for market share. These players are on the run for solidifying their presence through the adoption of strategic plans such as collaborations, mergers, acquisitions and political support. The organizations are focusing on innovating their product line to serve the vast population in diverse regions.

Some of the prominent players operating in the Apheresis market include:

Asahi Kasei Corporation

Braun Melsungen AG

Cerus Corporation

Fresenius Kabi

Haemonetics Corporation

Charles River Laboratories International, Inc.

Kaneka Corporation

Kawasumi Laboratories Inc.

Nikkiso Co. Ltd

Terumo BCT

Latest Developments

In September 2024, Fresenius Kabi announced the divestment of its IV manufacturing site in Chile to Medifarma, streamlining its production network as part of its Vision 2026 strategy.

In June 2024, Asahi Kasei Corporation introduced a new membrane system for the production of sterile water used in injections, enhancing its product offerings in the healthcare sector.

In August 2023, Terumo BCT, Inc. launched a training program initiative aimed at supporting cell and gene therapy manufacturers, which is expected to improve cell collection processes and boost therapeutic commercialization.

In March 2024, Haemonetics Corporation received FDA approval for its new apheresis device designed to enhance the efficiency of blood component collection, marking a significant advancement in their product line.